Cytotheryx, a growing biotech firm working on treatments for liver disease, recently paid a combined $7.6 million to buy the two Rochester facilities it occupies. Cytotheryx, which uses genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results